Life Technologies announced the launch of Pervenio Lung RS. First-of-its-kind, the molecular test has been documented to reliably identify early stage lung cancer patients who are at high risk for mortality following surgery. The market size for an early stage molecular test is estimated to be approximately $120M in the United States and $500M globally, the company said.
- Tests & Procedures
- Life Technologies